EUCTR2017-000614-39-NO
Active, not recruiting
Phase 1
Prevention of graft-versus-host disease in patients treated with allogeneic stem cell transplantation: Possible role of extracorporeal photophoresis
OSLO UNIVERSITY HOSPITAL HF0 sites156 target enrollmentStarted: March 1, 2017Last updated:
Overview
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- OSLO UNIVERSITY HOSPITAL HF
- Enrollment
- 156
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients \> 18 yrs diagnosed with acute or chronic leukemia, chronic myeloproliferative disease, myelodysplastic syndromes and lymphomas according to WHO\-criteria and that are suitable fora first\-time allogeneic stem cell transplatation according to our national guidelines.
- •\-Provide written consent to participate
- •\-Understand Norwegian or English
- •\-No previous history of malignant disease
- •\-No contraindication to ECP\-treatment or undergone previous ECP treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 120
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •In addition to those regarding eligibility for transplantation itself:
- •\-Unwilling to provide written consent to participate
- •\-Unable to cooperate as judged by the responsible physician
- •\-ECOG status \> 2 at time of inclusion
- •\-Using anti\-inflammatory or cytotoxic drugs other than those that are part of the treatment of the current hematological malignancy
- •\-Known allergy to psoralen or citrate products
Investigators
Similar Trials
Recruiting
Phase 2
Single agent GVHD prophylaxis with PTCY for SCT: a phase II studyeukemia/lymphomaHematologic malignancyJPRN-jRCTs031180399Sakaguchi Hirotoshi30
Recruiting
Not Applicable
Single agent graft-versus-host disease prophylaxis with post-transplant cyclophosphamide for stem cell transplantation: a phase II study (SAP-P2)Acute leukemiaJPRN-UMIN000021375ational Center for Child Health and Development30
Active, not recruiting
Phase 1
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-thymocyte-globulin (ATG) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study - NDAcute myeloid leukemia in first or subsequent complete remissionMedDRA version: 9.1Level: HLTClassification code 10024291Term: Leukaemias acute myeloidEUCTR2005-005719-83-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI160
Active, not recruiting
Not Applicable
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-Tlymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantantioAcute lymphoblastic and myeloid leukemiaMedDRA version: 14.1Level: LLTClassification code 10000842Term: Acute lymphatic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2005-005719-83-ESniversitary Hospital Hamburg160
Active, not recruiting
Not Applicable
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study - not availableacute lymphoblastic and myeloid leukemiaMedDRA version: 8.1Level: LLTClassification code 10024330Term: Leukemia acuteEUCTR2005-005719-83-DEniversity Hospital Hamburg-Eppendorf160